Tonix Pharmaceuticals Holding Past Earnings Performance
Past criteria checks 0/6
Tonix Pharmaceuticals Holding's earnings have been declining at an average annual rate of -36.3%, while the Biotechs industry saw earnings growing at 16.9% annually.
Key information
-36.3%
Earnings growth rate
115.9%
EPS growth rate
Biotechs Industry Growth | -14.6% |
Revenue growth rate | n/a |
Return on equity | -70.6% |
Net Margin | n/a |
Last Earnings Update | 31 Mar 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Tonix Pharmaceuticals Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 23 | 0 | -123 | 30 | 90 |
31 Dec 22 | 0 | -117 | 30 | 82 |
30 Sep 22 | 0 | -112 | 29 | 79 |
30 Jun 22 | 0 | -102 | 27 | 70 |
31 Mar 22 | 0 | -98 | 26 | 72 |
31 Dec 21 | 0 | -92 | 23 | 69 |
30 Sep 21 | 0 | -80 | 21 | 59 |
30 Jun 21 | 0 | -73 | 19 | 54 |
31 Mar 21 | 0 | -64 | 17 | 47 |
31 Dec 20 | 0 | -52 | 14 | 36 |
30 Sep 20 | 0 | -46 | 12 | 30 |
30 Jun 20 | 0 | -42 | 12 | 26 |
31 Mar 20 | 0 | -34 | 11 | 19 |
31 Dec 19 | 0 | -31 | 11 | 18 |
30 Sep 19 | 0 | -31 | 10 | 18 |
30 Jun 19 | 0 | -28 | 10 | 16 |
31 Mar 19 | 0 | -29 | 9 | 16 |
31 Dec 18 | 0 | -29 | 9 | 18 |
30 Sep 18 | 0 | -24 | 8 | 16 |
30 Jun 18 | 0 | -24 | 8 | 17 |
31 Mar 18 | 0 | -23 | 8 | 16 |
31 Dec 17 | 0 | -21 | 8 | 13 |
30 Sep 17 | 0 | -23 | 9 | 15 |
30 Jun 17 | 0 | -25 | 9 | 15 |
31 Mar 17 | 0 | -30 | 9 | 21 |
31 Dec 16 | 0 | -39 | 10 | 29 |
30 Sep 16 | 0 | -45 | 12 | 33 |
30 Jun 16 | 0 | -50 | 13 | 39 |
31 Mar 16 | 0 | -52 | 13 | 39 |
31 Dec 15 | 0 | -48 | 13 | 36 |
30 Sep 15 | 0 | -44 | 12 | 32 |
30 Jun 15 | 0 | -38 | 11 | 27 |
31 Mar 15 | 0 | -32 | 10 | 22 |
31 Dec 14 | 0 | -28 | 9 | 19 |
30 Sep 14 | 0 | -22 | 8 | 14 |
30 Jun 14 | 0 | -18 | 7 | 11 |
31 Mar 14 | 0 | -14 | 7 | 7 |
31 Dec 13 | 0 | -11 | 6 | 5 |
30 Sep 13 | 0 | -10 | 5 | 4 |
30 Jun 13 | 0 | -8 | 5 | 3 |
31 Mar 13 | 0 | -9 | 5 | 3 |
31 Dec 12 | 0 | -9 | 4 | 3 |
Quality Earnings: TPM0 is currently unprofitable.
Growing Profit Margin: TPM0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TPM0 is unprofitable, and losses have increased over the past 5 years at a rate of 36.3% per year.
Accelerating Growth: Unable to compare TPM0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TPM0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: TPM0 has a negative Return on Equity (-70.61%), as it is currently unprofitable.